Abstract:The field of stem cell biology and regenerative medicine is rapidly moving toward translation to clinical practice, and in doing so has become even more dependent on animal donors and hosts for generating cellular reagents and assaying their potential therapeutic efficacy in models of human disease. Advances in cell culture technologies have revealed a remarkable plasticity of stem cells from embryonic and adult tissues, and transplantation models are now needed to test the ability of these cells to protect at-risk cells and replace cells lost to injury or disease. With such a mandate, issues related to acceptable sources and controversial (e.g., chimeric) models have challenged the field to provide justification of their potential efficacy before the passage of new restrictions that may curb anticipated breakthroughs. Progress from the use of both in vitro and in vivo regenerative medicine models already offers hope both for the facilitation of stem cell phenotyping in recursive gene expression profile models and for the use of stem cells as powerful new therapeutic reagents for cancer, stroke, Parkinson's, and other challenging human diseases that result in movement disorders. This article describes research in support of the following three objectives: (1) To discover the best stem or progenitor cell in vitro protocols for isolating, expanding, and priming these cells to facilitate their massive propagation into just the right type of neuronal precursor cell for protection or replacement protocols for brain injury or disease, including those that affect movement such as Parkinson's disease and stroke; (2) To discover biogenic factors--compounds that affect stem/progenitor cells (e.g., from high-throughput screening and other bioassay approaches)--that will encourage reactive cell genesis, survival, selected differentiation, and restoration of connectivity in central nervous system movement and other disorders; and (3) To establish the best animal models of human disease and injury, using both small and large animals, for testing new regenerative medicine therapeutics.

Primate Stem Cells: Bridge the Translation from Basic Research to Clinic Application

Paving the Road for Biomedicine: Genome Editing and Stem Cells in Primates

Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans

Toward cell replacement therapy: promises and caveats

Primate Primordial Germ Cells Acquire Transplantation Potential by Carnegie Stage 23

Thoughts on advancing the stem cell clinical research

Stem cells, regenerative medicine, and animal models of disease

Induced Neural Stem/precursor Cells for Fundamental Studies and Potential Application in Neurodegenerative Diseases

Update on Hematopoietic Stem Cell Gene Transfer Using Non-Human Primate Models.

Non-human Primate Regulatory T Cells and Their Assessment as Cellular Therapeutics in Preclinical Transplantation Models

Conversion of Monkey Fibroblasts to Transplantable Telencephalic Neuroepithelial Stem Cells.

Embryo-Engineered Nonhuman Primate Models: Progress and Gap to Translational Medicine

Developing Humanized Animal Models with Transplantable Human iPSC-Derived Cells

Transplantable Neural Progenitor Populations Derived from Rhesus Monkey Embryonic Stem Cells.

Primary Culture of Germ Cells That Portray Stem Cell Characteristics and Recipient Preparation for Autologous Transplantation in the Rhesus Monkey

Translational Research and Therapeutic Applications of Stem Cell Transplantation in Periodontal Regenerative Medicine

Why Non-Human Primates Are Needed in Stroke Preclinical Research

Characterization of Human-Induced Neural Stem Cells and Derivatives following Transplantation into the Central Nervous System of a Nonhuman Primate and Rats

Non-human primate models of focal cortical ischemia for neuronal replacement therapy

Regeneration Next: Toward Heart Stem Cell Therapeutics

Hot spots in fundamental stem cell research and their difficulties in application studies